PURE EP System Pre-Clinical Data to be Presented at the 13th International Dead Sea Symposium (IDSS)

Minneapolis, MN, March 02, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM) today announced that pre-clinical data, gathered during a series of studies from 2015 at the Mayo Clinic, will be presented at the 13th International Dead Sea Symposium on Innovations in Cardiac Arrhythmias and Device Therapy at the David Intercontinental Convention Center in Tel Aviv, Israel.

Ammar Killu, MBBS of the Mayo Clinic in Rochester, Minnesota will present Enhanced Electrophysiology Recording Improves Signal Acquisition and Differentiation on March 8, 2016 at 18:10 in Hall A.

Greg Cash, President and Chief Executive Officer of BioSig Technologies, stated, “These important pre-clinical data characterize the PURE EP System’s ability to improve acquisition and visualization of high fidelity cardiac signals, and is an important milestone for the company. We have been very pleased with our collaboration with Dr. Samuel Asirvatham and his team and look forward to continuing this work at the Mayo Clinic.”

About BioSig Technologies

BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $3 billion EP marketplace. Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.

The PURE EP™ System is a surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).

Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019, making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017.
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation through UCLA labs, and has performed pre-clinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation’s most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.


2HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.

Contact:
Investor Relations:
Brian McLaughlin
BioSig Technologies, Inc.
bmclaughlin@biosigtech.com
917-370-9817

Source: BioSig Technologies, Inc.